Author

M. Pedotti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 5 Approach:experimental assay· 4 Organism:human· 4 Assay:proteomics· 2 Organism:mouse· 1

Frequent Co-Authors

L. Simonelli· 4 shared A. Piralla· 3 shared F. Baldanti· 3 shared F. Bianchini· 3 shared L. Calzolai· 3 shared L. Varani· 3 shared A. A. Shanbhag· 2 shared A. Cavalli· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

L. Simonelli

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages

H. Marcotte, Y. Cao, F. Zuo, L. Simonelli, J. C. Sammartino, M. Pedotti, R. Sun, I. Cassaniti, M. Hagbom, A. Piralla, J. Yang, L. Du, E. Percivalle, F. Bertoglio, M. Schubert, , Q. Pan-Hammarstrom

Engineered dimeric and secretory IgA1 neutralized Omicron variants with higher potency than parental IgG.

Proceedings of the National Academy of Sciences · Jan 9, 2024Peer-reviewedMicrobiology

Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2

F. Bianchini, V. Crivelli, M. E. Abernathy, C. Guerra, M. Palus, J. Muri, H. Marcotte, A. Piralla, M. Pedotti, R. De, L. Simonelli, M. Matkovic, C. Toscano, M. Biggiogero, V. Calvaruso, , Ru

The paper identifies broadly cross-reactive neutralizing antibodies against SARS-CoV-2 variants using coldspot-guided antibody discovery.

bioRxiv · Nov 24, 2022 · PreprintImmunology

Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course

J. Muri, V. Cecchinato, A. Cavalli, A. A. Shanbhag, M. Matkovic, M. Biggiogero, P. A. Maida, J. Moritz, C. Toscano, E. Ghovehoud, R. Furlan, F. Barbic, A. Voza, G. De Nadai, C. Cervia, , Franzetti-Pelland

The paper finds that anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease outcomes and predict absence of long COVID symptoms.

bioRxiv · May 23, 2022 · PreprintImmunology

Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease

R. De Gasparo, M. Pedotti, L. Simonelli, P. Nickl, F. Muecksch, I. Cassaniti, E. Percivalle, J. C. C. Lorenzi, F. Mazzola, D. Magri, T. Michalcikova, J. Haviernik, V. Honig, B. Mrazkova, N. Polakova, , T. Hatziioannou

bioRxiv · Jan 22, 2021 · PreprintImmunology

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface

F. Bertoglio, D. Meier, N. Langreder, S. Steinke, U. Rand, L. Simonelli, P. A. Heine, R. Ballmann, K.-T. Schneider, K. D. R. Roth, M. Ruschig, P. Riese, K. Eschke, Y. Kim, D. Schaeckermann, , M. Hust

The paper identifies potent SARS-CoV-2 neutralizing antibodies from pre-pandemic human donors that bind the RBD-ACE2 interface, showing high neutralization efficacy in vitro.

bioRxiv · Jun 5, 2020Biochemistry